This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01383-07v1 52/5/1653    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Lawrence, L. Articles by Sutcliffe, J. PubMed PubMed Citation Articles by Lawrence, L. Articles by Sutcliffe, J.

In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens

Rib-X Pharmaceuticals, Inc., 300 George Street, New Haven, Connecticut 06511

Received 25 October 2007/ Returned for modification 26 November 2007/ Accepted 22 February 2008

Rx-01_423 and Rx-01_667 are two members of the family of oxazolidinones that were designed using a combination of computational and medicinal chemistry and conventional biological techniques. The compounds have a two- to eightfold-improved potency over linezolid against serious gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant streptococci, and vancomycin-resistant enterococci. This enhanced potency extends to the coverage of linezolid-resistant gram-positive microbes, especially multidrug-resistant enterococci and pneumococci. Compounds from this series expand the spectrum compared with linezolid to include fastidious gram-negative organisms like Haemophilus influenzae and Moraxella catarrhalis. Like linezolid, the Rx-01 compounds are bacteriostatic against MRSA and enterococci but are generally bactericidal against S. pneumoniae and H. influenzae.

Published ahead of print on 3 March 2008.